From Cells to Insight
End-to-End 3D Neural Screening Services with RealBrain® Technology
Accelerate Preclinical Neuroscience Drug Discovery
Predictive. Scalable. Human-relevant.
Our proprietary 3D neural models—ARTIBrain™ and ADBrain™—deliver validated platforms for efficacy, safety, and mechanistic studies.
Designed for high-throughput applications, they produce consistent, translatable data to support confident decision-making.
Disease-Relevant Human Brain Models
ARTIBrain™ – Healthy Adult Brain Model
Captures baseline neural complexity for toxicity profiling and control comparisons.
ADBrain™ – Alzheimer’s Disease Model
Recapitulates amyloid aggregation, tau pathology, synaptic loss, and progressive neurodegeneration.Customised Model Development
Are developed using iPSC-derived neurons and glia, with genetic editing and co-culture to capture neurodegeneration and disease progression.
The RealBrain® Platform
Our Services
Neural Network Analysis: Maturation, network dynamics, plasticity, and compound response
Biomarker Discovery: Transcriptomic and proteomic profiling, cell composition analysis
Mechanism-of-Action Studies: Cell-specific responses, ferroptosis and novel pathways
Efficacy Screening: Functional readouts, inflammation profiling, dose-response
Safety & Toxicity Profiling: Acute/chronic neurotoxicity, oxidative stress, viability
High-Content Screening: AI-based multiparametric imaging and analysis
Target Validation: Human-relevant models, FDA/EMA-aligned reproducible data
Key Assays
Cytotoxicity & viability in acute & chronic
conditions
Neural morphology & plasticity assessed through
imaging & markers
Neuroinflammation profiling
Targeted protein profiling of neural markers &
cellular composition
Omics profiling
Build Better Data with 3D Neural Tissues—Let’s Work Together
Ready to Start Your Study?
Let’s discuss how our end-to-end services can support your next compound screen, biomarker project, or preclinical program.
Our research and development partners
Industry affiliations and corporate development partners
